A new vaccine against corona targeting long-term immunity passes the first stage
Wednesday – 19 Rabi’ al-Thani 1443 AH – 24 November 2021 AD
Berlin: «Middle East Online»
A group of German scientists announced the successful completion of the first phase of clinical tests for a vaccine against the Corona virus, according to the Russian “Novosti” news agency.
According to the agency, the new vaccine aims to create a long-term immunity to T-cells against “Covid-19”.
And “Nature” indicates that the tests were conducted at the University Hospital Tübingen, and their results showed that all participants in the tests (36 volunteers) received one dose of the new CoVac-1 vaccine, and they showed a stronger immune response to T cells than those that arise as a result of infection the emerging coronavirus, and it lasted three months; It is the period since they were vaccinated.
T-cell immunity is the body’s first line of defense against pathogens. These cells attack the infected cells and send information to the B cells that produce the antibodies.
A good T-cell immune response is especially important for people with B-cell deficiency, such as cancer patients or immunocompromised patients.
The results of the first phase of clinical trials of the CoVac-1 vaccine showed effectiveness and no side effects in all participants between the ages of 18 and 80 years. It also turned out that the vaccine is effective against all variants of the emerging coronavirus.
For their part, the researchers evaluate these results completely positive and hope to confirm them in the second phase of clinical trials, which will start soon.
new corona virus